619 related articles for article (PubMed ID: 21909130)
1. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
Astle MV; Hannan KM; Ng PY; Lee RS; George AJ; Hsu AK; Haupt Y; Hannan RD; Pearson RB
Oncogene; 2012 Apr; 31(15):1949-62. PubMed ID: 21909130
[TBL] [Abstract][Full Text] [Related]
2. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53.
Jung SH; Hwang HJ; Kang D; Park HA; Lee HC; Jeong D; Lee K; Park HJ; Ko YG; Lee JS
Oncogene; 2019 Mar; 38(10):1639-1650. PubMed ID: 30337688
[TBL] [Abstract][Full Text] [Related]
3. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
4. Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway.
Havel JJ; Li Z; Cheng D; Peng J; Fu H
Oncogene; 2015 Mar; 34(12):1487-98. PubMed ID: 24704832
[TBL] [Abstract][Full Text] [Related]
5. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
6. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
Kim JS; Lee C; Bonifant CL; Ressom H; Waldman T
Mol Cell Biol; 2007 Jan; 27(2):662-77. PubMed ID: 17060456
[TBL] [Abstract][Full Text] [Related]
7. Tumorigenic activity and therapeutic inhibition of Rheb GTPase.
Mavrakis KJ; Zhu H; Silva RL; Mills JR; Teruya-Feldstein J; Lowe SW; Tam W; Pelletier J; Wendel HG
Genes Dev; 2008 Aug; 22(16):2178-88. PubMed ID: 18708578
[TBL] [Abstract][Full Text] [Related]
8. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
9. Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence.
Xu Y; Li N; Xiang R; Sun P
Trends Biochem Sci; 2014 Jun; 39(6):268-76. PubMed ID: 24818748
[TBL] [Abstract][Full Text] [Related]
10. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.
Italiano A; Chen CL; Thomas R; Breen M; Bonnet F; Sevenet N; Longy M; Maki RG; Coindre JM; Antonescu CR
Cancer; 2012 Dec; 118(23):5878-87. PubMed ID: 22648906
[TBL] [Abstract][Full Text] [Related]
11. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.
Jefferies MT; Cox AC; Shorning BY; Meniel V; Griffiths D; Kynaston HG; Smalley MJ; Clarke AR
J Pathol; 2017 Dec; 243(4):442-456. PubMed ID: 29134654
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Yang NY; Fernandez C; Richter M; Xiao Z; Valencia F; Tice DA; Pasquale EB
Cell Signal; 2011 Jan; 23(1):201-12. PubMed ID: 20837138
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Davis NM; Sokolosky M; Stadelman K; Abrams SL; Libra M; Candido S; Nicoletti F; Polesel J; Maestro R; D'Assoro A; Drobot L; Rakus D; Gizak A; Laidler P; Dulińska-Litewka J; Basecke J; Mijatovic S; Maksimovic-Ivanic D; Montalto G; Cervello M; Fitzgerald TL; Demidenko Z; Martelli AM; Cocco L; Steelman LS; McCubrey JA
Oncotarget; 2014 Jul; 5(13):4603-50. PubMed ID: 25051360
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic Roles of the PI3K/AKT/mTOR Axis.
Aoki M; Fujishita T
Curr Top Microbiol Immunol; 2017; 407():153-189. PubMed ID: 28550454
[TBL] [Abstract][Full Text] [Related]
15. Cooperation between p21 and Akt is required for p53-dependent cellular senescence.
Kim YY; Jee HJ; Um JH; Kim YM; Bae SS; Yun J
Aging Cell; 2017 Oct; 16(5):1094-1103. PubMed ID: 28691365
[TBL] [Abstract][Full Text] [Related]
16. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
17. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.
Steelman LS; Navolanic P; Chappell WH; Abrams SL; Wong EW; Martelli AM; Cocco L; Stivala F; Libra M; Nicoletti F; Drobot LB; Franklin RA; McCubrey JA
Cell Cycle; 2011 Sep; 10(17):3003-15. PubMed ID: 21869603
[TBL] [Abstract][Full Text] [Related]
18. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
19. Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduits.
Mitra AK; Jia G; Gangahar DM; Agrawal DK
J Cell Mol Med; 2009 Jan; 13(1):177-87. PubMed ID: 18363844
[TBL] [Abstract][Full Text] [Related]
20. [Role of MEK/ERK pathway in the regulation of HDACI-induced senescence of transformed rat embryo fibroblasts].
Kochetkova EIu; Bykova TV; Zubova SG; Pospelova TV
Tsitologiia; 2014; 56(8):581-90. PubMed ID: 25697003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]